

PROMISSORY NOTE AMENDMENT
(the “**Amending Agreement**”)

Borrower: ZYUS Life Sciences Inc. (Business No.: 76136 4710 RT0001)

Borrower’s Mailing Address: 204-407 Downey Road, Saskatoon, Saskatchewan, S7N 4L8

Lender: 102042227 Saskatchewan Ltd.

Effective Date: October 16, 2025

WHEREAS:

- A. The Borrower and Brent Zettl entered into a Promissory Note dated March 31, 2021 (the “**Promissory Note**”) having a maturity date of March 31, 2023;
- B. The Promissory Note was transferred by Brent Zettl to the Lender on May 19, 2021;
- C. On December 22, 2021, the Lender waived the interest payment due on January 30, 2022 under the Promissory Note in perpetuity until such time as the Company had sufficient working capital and deemed it appropriate to pay the interest;
- D. The Promissory Note was amended on June 30, 2022 to amend the maturity date from March 31, 2023 to March 31, 2024 (the “**March 2024 Maturity Date**”);
- E. The March 2024 Maturity Date was amended on January 29, 2023 to amend the maturity date from March 31, 2024 to June 30, 2024 (the “**June 2024 Maturity Date**”);
- F. The June 2024 Maturity Date was amended on June 27, 2024 to amend the maturity date from June 30, 2024 to December 31, 2024 (the “**December 2024 Maturity Date**”);
- G. The December 2024 Maturity Date was amended on December 20, 2024 to amend the maturity date from December 31, 2024 to December 31, 2025 (the “**December 2025 Maturity Date**”);
- H. On December 20, 2024, the interest rate payable in respect of the amounts outstanding under the under the Promissory Note, as amended from time to time as set out above (the “**Amended Promissory Note**”) was increased perpetually to 12% per annum;
- I. As of the date hereof, \$4,267,388.67 in principal amount and \$279,192.44 in accrued interest are outstanding under the Amended Promissory Note; and
- J. The Borrower and Lender wish to further amend the Amended Promissory Note on the terms and conditions contained in this Amending Agreement.

NOW THEREFORE THIS AMENDING AGREEMENT WITNESSTH THAT, in consideration of the premises set forth above and other good and valuable consideration, the Borrower will issue the Lender certain warrants as evidenced by a warrant certificate to be provided to the Lender by the Borrower upon the receipt of approval from the TSX Venture Exchange and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. Capitalized terms used in this Amending Agreement and not otherwise defined herein shall have the meanings ascribed to them in the Amended Promissory Note.
2. The Parties agree that:
 - a. on the Effective Date of this Amending Agreement:
 - i. the Maturity Date shall be amended to December 31, 2027 (the “**December 2027 Maturity Date**”);
 - ii. the Interest Payment terms shall be amended to provide that all interest accrued and unpaid prior to the Effective Date, including but not limited to the interest waived by the Lender on December 22, 2021, and all interest accruing following the Effective Date shall be payable on earlier of: (A) the December 2027 Maturity Date, or (B) within 30 days of the Borrower electing to prepay, in full, all amounts owing to the Lender in accordance with the terms of the Amended Promissory Note, as amended herein; and
3. Save as amended by this Amending Agreement, the Borrower and Lender confirm and ratify all of the terms and conditions set forth in the Amended Promissory Note and agree that the same shall continue in full force and effect.
4. At the request of the Lender, the Borrower shall deliver to the Lender an amended and restated promissory note setting forth the terms and conditions of the Amended Promissory Note, as amended by this Amending Agreement.
5. This Amending Agreement shall be binding upon and shall enure to the benefit of the parties hereto and their respective successors and assigns.
6. This Amending Agreement may be signed in any number of counterparts. Each such counterpart shall, for all purposes, be deemed an original. All such counterparts together shall constitute but one and the same agreement. An electronic facsimile transmission hereof signed by any person named below will be sufficient to establish the signature of that person and to constitute the consent in writing of that person to the foregoing agreement and, notwithstanding the date of execution, shall be deemed to be executed as of the date set forth above.

[SIGNATURE PAGE TO FOLLOW]

IN WITNESS WHEREOF the undersigned have duly executed this Amending Agreement as of the date first written above.

ZYUS LIFE SCIENCES INC.

(signed) "*John Hyshka*"

By: _____

Name: John Hyshka
Title: CFO

102042227 SASKATCHEWAN LTD.

(signed) "*Brent Zettl*"

By: _____

Name: Brent Zettl
Title: Director